231 related articles for article (PubMed ID: 27958325)
1. OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study.
Jiang YH; Wang CC; Kuo HC
Sci Rep; 2016 Dec; 6():38905. PubMed ID: 27958325
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity.
Jiang YH; Chen SF; Jhang JF; Kuo HC
Neurourol Urodyn; 2018 Nov; 37(8):2651-2657. PubMed ID: 29797345
[TBL] [Abstract][Full Text] [Related]
3. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.
Jiang YH; Jhang JF; Chen SF; Kuo HC
Low Urin Tract Symptoms; 2019 Jan; 11(1):66-71. PubMed ID: 29024564
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions.
Lee YK; Kuo HC
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31450851
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction.
Kao YL; Huang KH; Kuo HC; Ou YC
Toxins (Basel); 2019 Dec; 11(12):. PubMed ID: 31847090
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women.
Jiang YH; Lee CL; Chen SF; Kuo HC
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069448
[TBL] [Abstract][Full Text] [Related]
7. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.
Kuo HC
Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645
[TBL] [Abstract][Full Text] [Related]
8. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.
't Hoen LA; van den Hoek J; Wolffenbuttel KP; van der Toorn F; Scheepe JR
J Pediatr Urol; 2015 Jun; 11(3):119.e1-6. PubMed ID: 25794865
[TBL] [Abstract][Full Text] [Related]
9. Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection.
Kao YL; Ou YC; Tsai KJ; Kuo HC
Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548774
[TBL] [Abstract][Full Text] [Related]
10. Urethral Sphincter Botulinum Toxin A Injection for Non-Spinal Cord Injured Patients with Voiding Dysfunction without Anatomical Obstructions: Which Patients Benefit Most?
Chen SF; Kuo HC
Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828402
[TBL] [Abstract][Full Text] [Related]
11. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients.
Gallien P; Reymann JM; Amarenco G; Nicolas B; de Sèze M; Bellissant E
J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1670-6. PubMed ID: 16291892
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction.
Lee CL; Jhang JF; Jiang YH; Kuo HC
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051007
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors.
Ou YC; Huang KH; Jan HC; Kuo HC; Kao YL; Tsai KJ
Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34199493
[TBL] [Abstract][Full Text] [Related]
14. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction.
Kuo HC
Urology; 2007 Jan; 69(1):57-61; discussion 61-2. PubMed ID: 17270614
[TBL] [Abstract][Full Text] [Related]
15. Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury.
Chen SL; Bih LI; Huang YH; Tsai SJ; Lin TB; Kao YL
J Rehabil Med; 2008 Oct; 40(9):744-8. PubMed ID: 18843427
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy.
Kuo HC
Urol Int; 2005; 75(3):247-51. PubMed ID: 16215314
[TBL] [Abstract][Full Text] [Related]
17. Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction.
Kuo HC
Ci Ji Yi Xue Za Zhi; 2016; 28(3):89-93. PubMed ID: 28757732
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
Leippold T; Reitz A; Schurch B
Eur Urol; 2003 Aug; 44(2):165-74. PubMed ID: 12875934
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.
Phelan MW; Franks M; Somogyi GT; Yokoyama T; Fraser MO; Lavelle JP; Yoshimura N; Chancellor MB
J Urol; 2001 Apr; 165(4):1107-10. PubMed ID: 11257648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
